News from the healthcare data industry
VANCOUVER, BC, Jan. 4, 2022 /CNW/ – On the 17th December 2021 the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) produced guidance acknowledging and setting out the criteria for the use of Real...
31 Dec 2021 NEWS Â Vibha Sharma Executive Summary The UK Medicines and Healthcare products Regulatory Agency has finalized the first part of a series of new guidance documents addressing issues...
By Mark McCarty The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has unveiled two guidances for the use of real-world evidence (RWE) in regulatory decision-making. The policy seems limited to pharmaceutical clinical...
1. Scope This document provides an introduction to the MHRA’s real-world data (RWD) guideline series, and points to consider when evaluating whether a RWD source is of sufficient quality for the...
1. Overview This guideline is aimed at sponsors who are planning to conduct a randomised, controlled clinical trial primarily using real-world data (RWD) sources to support a regulatory decision relating to...
STATION F is excited to welcome Palantir Technologies as a partner of the Foster the Future initiative, which will offer workshops and conferences to early-stage companies and allow them to...
SAN FRANCISCO, Dec. 06, 2021 (GLOBE NEWSWIRE) — Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, presented five abstracts...
NEW YORK, Dec. 6, 2021 /PRNewswire/ — Holmusk, a leading global data science and digital health company building the world’s largest Real-World Evidence (RWE) platform for behavioral health, today announced the closing of...
BERLIN, Nov. 23, 2021 /PRNewswire/ — Holmusk, a leading global data science and digital health company building the world’s largest Real-World Evidence (RWE) platform for mental health, has signed a Memorandum of...
BARCELONA, Spain, Dec. 1, 2021 /PRNewswire/ — The European Medicines Agency (EMA) has selected Aetion for a four-year term to support the agency’s Quality, Efficacy, and Safety Studies on Medicines. Aetion will...